Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptive Biotechnologies CorpADPT · Entity 1126 | Chief Financial Officer | December 22, 2021 | December 24, 2021 |
| Grindr Inc.GRND · Entity 1043 | Director | June 02, 2026 | June 04, 2026 |
| TRUPANION, INC.TRUP · Entity 4822 | Director | March 31, 2019 | April 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptive Biotechnologies Corp
Report date December 22, 2021 · Filed December 24, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,604 |
Ending reported balance
After 2021-12-22 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-12-22 · Exercise / conversion · Acquired 10,000 · Balance 31,604 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Row 2 · 2021-12-22 · Sale · Disposed 10,000 · Balance 21,604 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 · Expires 2029-02-07 | Direct | 80,000 |
Reported balance
After 2021-12-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-22 · Exercise / conversion · Disposed 10,000 · Balance 80,000 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.
F2: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Grindr Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,596 |
Ending reported balance
After 2026-06-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-02 · Grant · Acquired 13,593 · Balance 24,547 F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs") granted on June 2, 2026. Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 1/4th of the RSUs vest and settle into Common Stock every three months on the same day of the month as the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2022 Equity Incentive Plan (the "2022 Plan")) through each such vesting date; provided, that the RSUs will in any event vest in full on the earlier to occur of (1) immediately prior to the Issuer's 2027 annual stockholder meeting, and (2) immediately prior to the effective time of a Change in Control (as defined in the 2022 Plan), subject to the Reporting Person's Continuous Service through the applicable time. Row 2 · 2026-06-02 · Grant · Acquired 4,049 · Balance 28,596 F2: Represents the number of shares of the Issuer's Common Stock underlying RSUs granted on June 2, 2026. Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 1/4th of the RSUs vest and settle into Common Stock every three months on the same day of the month as the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2022 Plan) through each such vesting date; provided, that the RSUs will vest in full immediately prior to the effective time of a Change in Control (as defined in the 2022 Plan), subject to the Reporting Person's Continuous Service through such time. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs") granted on June 2, 2026. Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 1/4th of the RSUs vest and settle into Common Stock every three months on the same day of the month as the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2022 Equity Incentive Plan (the "2022 Plan")) through each such vesting date; provided, that the RSUs will in any event vest in full on the earlier to occur of (1) immediately prior to the Issuer's 2027 annual stockholder meeting, and (2) immediately prior to the effective time of a Change in Control (as defined in the 2022 Plan), subject to the Reporting Person's Continuous Service through the applicable time.
F2: Represents the number of shares of the Issuer's Common Stock underlying RSUs granted on June 2, 2026. Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 1/4th of the RSUs vest and settle into Common Stock every three months on the same day of the month as the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2022 Plan) through each such vesting date; provided, that the RSUs will vest in full immediately prior to the effective time of a Change in Control (as defined in the 2022 Plan), subject to the Reporting Person's Continuous Service through such time.
TRUPANION, INC.
Report date March 31, 2019 · Filed April 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,119 |
Reported balance
After 2019-03-31 transaction · row 1
1 source rowRow 1 · 2019-03-31 · Exercise / conversion · Acquired 938 · Balance 4,119 F1: The RSU converts into common stock on a one-for-one basis. |
| Restricted Stock Unit (RSU)SEC Table II · derivative / convertible security · Conversion / exercise price $29.93 · Expires 2019-12-31 | Direct | 2,816 |
Reported balance
After 2019-03-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-31 · Exercise / conversion · Disposed 938 · Balance 2,816 F2: The RSU vests and will convert into common stock of the Issuer as to 25% of the total shares on each of March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019, subject to continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The RSU converts into common stock on a one-for-one basis.
F2: The RSU vests and will convert into common stock of the Issuer as to 25% of the total shares on each of March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019, subject to continued service through each vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Vacasa, Inc.
Report date April 30, 2025 · Filed May 01, 2025
Section 16 reporting ended · disclosed 2025-05-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2025-04-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-04-30 · Conversion · Acquired 8,158 · Balance 38,538 F1: Pursuant to that certain Agreement and Plan of Merger, dated December 30, 2024 and amended on March 17, 2025 and March 28, 2025 (as amended to date, the "Merger Agreement"), by and among the Issuer, Vacasa Holdings LLC, Casago Holdings, LLC ("Parent"), Vista Merger Sub II Inc., a wholly owned subsidiary of Parent ("Company Merger Sub"), and Vista Merger Sub LLC, a wholly owned subsidiary of Parent ("LLC Merger Sub" and together with Company Merger Sub, "Merger Subs"), LLC Merger Sub merged with and into Vacasa Holdings LLC with Vacasa Holdings LLC surviving such merger as a subsidiary of Parent (the "LLC Merger"), and immediately after the LLC Merger, Company Merger Sub merged with and into the Issuer (the "Issuer Merger" and, together with the LLC Merger, the "Mergers"), with the Issuer surviving such merger as a wholly owned subsidiary of Parent and Vacasa Holdings LLC indirectly becoming a wholly owned subsidiary of Parent. F2: Immediately prior to the LLC Merger, the Common Units of Vacasa Holdings LLC were redeemed pursuant to which such Common Units and such shares of Class B Common Stock were exchanged for shares of Class A Common Stock in accordance with the Vacasa LLC Agreement. The newly issued shares of Class A Common Stock are entitled to the Merger Consideration (as defined below). Row 2 · 2025-04-30 · Disposition to issuer · Disposed 38,538 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated December 30, 2024 and amended on March 17, 2025 and March 28, 2025 (as amended to date, the "Merger Agreement"), by and among the Issuer, Vacasa Holdings LLC, Casago Holdings, LLC ("Parent"), Vista Merger Sub II Inc., a wholly owned subsidiary of Parent ("Company Merger Sub"), and Vista Merger Sub LLC, a wholly owned subsidiary of Parent ("LLC Merger Sub" and together with Company Merger Sub, "Merger Subs"), LLC Merger Sub merged with and into Vacasa Holdings LLC with Vacasa Holdings LLC surviving such merger as a subsidiary of Parent (the "LLC Merger"), and immediately after the LLC Merger, Company Merger Sub merged with and into the Issuer (the "Issuer Merger" and, together with the LLC Merger, the "Mergers"), with the Issuer surviving such merger as a wholly owned subsidiary of Parent and Vacasa Holdings LLC indirectly becoming a wholly owned subsidiary of Parent. F3: Upon consummation of the Company Merger, each (i) outstanding share of Class A Common Stock was automatically converted into the right to receive $5.30 in cash (the "Merger Consideration") and (ii) outstanding award of restricted stock units automatically converted into the right to receive the product of (a) the aggregate number of shares of Class A Common Stock underlying such award and (b) the Merger Consideration, subject to applicable vesting terms. |
| Vacasa Employee Holdings LLC InterestsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-04-30 · Conversion · Disposed 8,158 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated December 30, 2024 and amended on March 17, 2025 and March 28, 2025 (as amended to date, the "Merger Agreement"), by and among the Issuer, Vacasa Holdings LLC, Casago Holdings, LLC ("Parent"), Vista Merger Sub II Inc., a wholly owned subsidiary of Parent ("Company Merger Sub"), and Vista Merger Sub LLC, a wholly owned subsidiary of Parent ("LLC Merger Sub" and together with Company Merger Sub, "Merger Subs"), LLC Merger Sub merged with and into Vacasa Holdings LLC with Vacasa Holdings LLC surviving such merger as a subsidiary of Parent (the "LLC Merger"), and immediately after the LLC Merger, Company Merger Sub merged with and into the Issuer (the "Issuer Merger" and, together with the LLC Merger, the "Mergers"), with the Issuer surviving such merger as a wholly owned subsidiary of Parent and Vacasa Holdings LLC indirectly becoming a wholly owned subsidiary of Parent. F2: Immediately prior to the LLC Merger, the Common Units of Vacasa Holdings LLC were redeemed pursuant to which such Common Units and such shares of Class B Common Stock were exchanged for shares of Class A Common Stock in accordance with the Vacasa LLC Agreement. The newly issued shares of Class A Common Stock are entitled to the Merger Consideration (as defined below). |
| Vacasa Holdings UnitsSEC Table II · derivative / convertible security | Direct | 8,158 |
Reported balance
After 2025-04-30 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-04-30 · Conversion · Acquired 8,158 · Balance 8,158 F1: Pursuant to that certain Agreement and Plan of Merger, dated December 30, 2024 and amended on March 17, 2025 and March 28, 2025 (as amended to date, the "Merger Agreement"), by and among the Issuer, Vacasa Holdings LLC, Casago Holdings, LLC ("Parent"), Vista Merger Sub II Inc., a wholly owned subsidiary of Parent ("Company Merger Sub"), and Vista Merger Sub LLC, a wholly owned subsidiary of Parent ("LLC Merger Sub" and together with Company Merger Sub, "Merger Subs"), LLC Merger Sub merged with and into Vacasa Holdings LLC with Vacasa Holdings LLC surviving such merger as a subsidiary of Parent (the "LLC Merger"), and immediately after the LLC Merger, Company Merger Sub merged with and into the Issuer (the "Issuer Merger" and, together with the LLC Merger, the "Mergers"), with the Issuer surviving such merger as a wholly owned subsidiary of Parent and Vacasa Holdings LLC indirectly becoming a wholly owned subsidiary of Parent. F2: Immediately prior to the LLC Merger, the Common Units of Vacasa Holdings LLC were redeemed pursuant to which such Common Units and such shares of Class B Common Stock were exchanged for shares of Class A Common Stock in accordance with the Vacasa LLC Agreement. The newly issued shares of Class A Common Stock are entitled to the Merger Consideration (as defined below). |
| Vacasa Holdings UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-04-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-04-30 · Conversion · Disposed 8,158 · Balance 0 F1: Pursuant to that certain Agreement and Plan of Merger, dated December 30, 2024 and amended on March 17, 2025 and March 28, 2025 (as amended to date, the "Merger Agreement"), by and among the Issuer, Vacasa Holdings LLC, Casago Holdings, LLC ("Parent"), Vista Merger Sub II Inc., a wholly owned subsidiary of Parent ("Company Merger Sub"), and Vista Merger Sub LLC, a wholly owned subsidiary of Parent ("LLC Merger Sub" and together with Company Merger Sub, "Merger Subs"), LLC Merger Sub merged with and into Vacasa Holdings LLC with Vacasa Holdings LLC surviving such merger as a subsidiary of Parent (the "LLC Merger"), and immediately after the LLC Merger, Company Merger Sub merged with and into the Issuer (the "Issuer Merger" and, together with the LLC Merger, the "Mergers"), with the Issuer surviving such merger as a wholly owned subsidiary of Parent and Vacasa Holdings LLC indirectly becoming a wholly owned subsidiary of Parent. F2: Immediately prior to the LLC Merger, the Common Units of Vacasa Holdings LLC were redeemed pursuant to which such Common Units and such shares of Class B Common Stock were exchanged for shares of Class A Common Stock in accordance with the Vacasa LLC Agreement. The newly issued shares of Class A Common Stock are entitled to the Merger Consideration (as defined below). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to that certain Agreement and Plan of Merger, dated December 30, 2024 and amended on March 17, 2025 and March 28, 2025 (as amended to date, the "Merger Agreement"), by and among the Issuer, Vacasa Holdings LLC, Casago Holdings, LLC ("Parent"), Vista Merger Sub II Inc., a wholly owned subsidiary of Parent ("Company Merger Sub"), and Vista Merger Sub LLC, a wholly owned subsidiary of Parent ("LLC Merger Sub" and together with Company Merger Sub, "Merger Subs"), LLC Merger Sub merged with and into Vacasa Holdings LLC with Vacasa Holdings LLC surviving such merger as a subsidiary of Parent (the "LLC Merger"), and immediately after the LLC Merger, Company Merger Sub merged with and into the Issuer (the "Issuer Merger" and, together with the LLC Merger, the "Mergers"), with the Issuer surviving such merger as a wholly owned subsidiary of Parent and Vacasa Holdings LLC indirectly becoming a wholly owned subsidiary of Parent.
F2: Immediately prior to the LLC Merger, the Common Units of Vacasa Holdings LLC were redeemed pursuant to which such Common Units and such shares of Class B Common Stock were exchanged for shares of Class A Common Stock in accordance with the Vacasa LLC Agreement. The newly issued shares of Class A Common Stock are entitled to the Merger Consideration (as defined below).
F3: Upon consummation of the Company Merger, each (i) outstanding share of Class A Common Stock was automatically converted into the right to receive $5.30 in cash (the "Merger Consideration") and (ii) outstanding award of restricted stock units automatically converted into the right to receive the product of (a) the aggregate number of shares of Class A Common Stock underlying such award and (b) the Merger Consideration, subject to applicable vesting terms.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 09, 2021 Filed Jun 10, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $35.60 | $356,000.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $35.26 to 35.825, inclusive. Read SEC document |
| June 09, 2021 Filed Jun 10, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,599 | $37.85 | $60,522.15 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $37.64 to 38.03, inclusive. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 8,401 | $36.90 | $309,996.90 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,203 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $36.58 to 37.18, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-039637 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| May 12, 2021 Filed May 13, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · derivative · entry 7 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F6 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 12, 2021 Filed May 13, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $32.63 | $326,300.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $32.21 to 32.82, inclusive. Read SEC document |
| May 12, 2021 Filed May 13, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.55 | $0.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 7,031 | $31.84 | $223,867.04 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $31.52 to 32.12, inclusive. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,969 | $30.81 | $91,474.89 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,635 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $30.488 to 31.48, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| May 11, 2021 Filed May 13, 2021 23:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.55 | $65,500.00 |
DisclosureSEC source: 0001209191-21-032438 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · derivative · entry 7 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 10,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 806 | $42.34 | $34,126.04 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,194 | $41.59 | $382,378.46 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,410 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.26 to 41.98, inclusive. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.32 | $63,200.00 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| April 06, 2021 Filed Apr 9, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · derivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 10,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 06, 2021 Filed Apr 9, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $40.95 | $409,500.00 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.60 to 41.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| April 06, 2021 Filed Apr 9, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.32 | $63,200.00 |
DisclosureSEC source: 0001209191-21-026183 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-020302 · doc4.xml · derivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 10,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,000 | $42.54 | $425,400.00 |
DisclosureSEC source: 0001209191-21-020302 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.90 to 42.825, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 10, 2021 Filed Mar 13, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.32 | $63,200.00 |
DisclosureSEC source: 0001209191-21-020302 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-019621 · doc4.xml · derivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 10,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,890 | $40.79 | $117,883.10 |
DisclosureSEC source: 0001209191-21-019621 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,064 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $40.57 to 41.09, inclusive. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 7,110 | $40.02 | $284,542.20 |
DisclosureSEC source: 0001209191-21-019621 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,954 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $39.50 to 40.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 10,000 | $6.32 | $63,200.00 |
DisclosureSEC source: 0001209191-21-019621 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,064 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantStock Option (Right to Buy) · Derivative | 51,511 | $0.00 Strike: $43.68 | $0.00 |
DisclosureSEC source: 0001209191-21-018738 · doc4.xml · derivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,511 Underlying: Common Stock · 51,511 shares Expires 2021-03-04 F1 · derivative.exercise_date: The options vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. Read SEC document |
| March 04, 2021 Filed Mar 9, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | GrantCommon Stock | 20,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018738 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,604 Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · derivative · entry 10 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 50,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 2,184 | $57.70 | $126,016.80 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 8 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.34 to 58.18, inclusive. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 9,704 | $56.68 | $550,022.72 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 7 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,184 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.34 to 57.33, inclusive. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 38,112 | $55.77 | $2,125,506.24 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,888 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.14 to 56.12, inclusive. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 50,000 | $6.32 | $316,000.00 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · derivative · entry 9 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 50,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F8 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 18,523 | $57.00 | $1,055,811.00 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.51 to $57.155, inclusive. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 23,698 | $56.00 | $1,327,088.00 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,523 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.50 to 56.48, inclusive. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 7,779 | $55.04 | $428,156.16 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,221 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.50 to 55.49, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
| January 28, 2021 Filed Feb 2, 2021 01:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 50,000 | $6.32 | $316,000.00 |
DisclosureSEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 1 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · derivative · entry 12 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 50,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 5,920 | $65.47 | $387,582.40 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 10 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F9 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.31 to 66.01, inclusive. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 20,785 | $64.54 | $1,341,463.90 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 9 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,920 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F8 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.285 to 65.255, inclusive. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 12,977 | $63.65 | $825,986.05 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 8 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,705 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $63.14 to 64.04, inclusive. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,318 | $62.71 | $647,041.78 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 7 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,682 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $62.14 to 63.12, inclusive. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionCommon Stock | 50,000 | $6.32 | $316,000.00 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 6 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $6.32 | $0.00 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · derivative · entry 11 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,000 Underlying: Common Stock · 50,000 shares Expires 2025-08-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F10 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 1,000 | $67.68 | $67,680.00 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 5 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $67.56 to 67.79, inclusive. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 17,436 | $67.03 | $1,168,735.08 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 4 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $66.55 to $67.53, inclusive. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 20,953 | $65.69 | $1,376,402.57 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 3 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,436 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $65.35 to 66.32, inclusive. Read SEC document |
| January 25, 2021 Filed Jan 28, 2021 00:00 UTC | Adaptive Biotechnologies Corp ADPT · Entity 1126 | SaleCommon Stock | 10,611 | $65.08 | $690,563.88 |
DisclosureSEC source: 0001209191-21-005751 · doc4.xml · nonDerivative · entry 2 Cohen Chad M · CIK 0001524314 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,389 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020. F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $64.35 to 65.345, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.